Taconic Biosciences and Cellaria Biosciences collaborate to facilitate xenograft use in oncology research
Taconic Biosciences and Cellaria Biosciences announced that the two companies have entered into a scientific collaboration designed to facilitate and improve the utility of patient-derived xenografts (PDXs) in animal models for oncology and immuno-oncology research. Cellaria’s methodologies for generating cells from patient tumors will complement Taconic’s portfolio of tissue humanized mouse models, which are well-suited as hosts for PDXs.
The value of using patient-derived tumors in oncology and immuno-oncology research has been well documented, but traditional methods of obtaining tumor cell material have proven labor-intensive and expensive, inhibiting researchers’ access to this material. Cellaria’s approach to propagating tumor cell material and generating PDX banks significantly reduces the associated labor and costs, making patient-derived tumor models more accessible to investigators.
Other news from the department business & finance
